<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Venous <z:hpo ids='HP_0001907'>thromboembolic disease</z:hpo> remains the commonest cause of maternal <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The management of thromboprophylaxis in high risk women during pregnancy is contentious </plain></SENT>
<SENT sid="2" pm="."><plain>Low molecular weight <z:chebi fb="0" ids="24505">heparins</z:chebi> (LMW) have theoretical advantages compared with unfractionated <z:chebi fb="5" ids="28304">heparin</z:chebi> and <z:chebi fb="8" ids="10033">warfarin</z:chebi> but have been poorly studied in pregnancy </plain></SENT>
<SENT sid="3" pm="."><plain>We report on the use of LMW <z:chebi fb="5" ids="28304">heparin</z:chebi> (Fragmin) as thromboprophylaxis in thirty four <z:e sem="disease" ids="C0242786" disease_type="Disease or Syndrome" abbrv="">high risk pregnancies</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the women had a previous <z:mp ids='MP_0005048'>thrombosis</z:mp> or a <z:mp ids='MP_0005048'>thrombosis</z:mp> in their current pregnancy +/- a recognised thrombophilic state (eleven had the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>Fragmin was given subcutaneously to maintain trough anti-Xa activity of 0.15-0.2 U/ml and 2 h post injection levels of 0.4-0.6 U/ml </plain></SENT>
<SENT sid="6" pm="."><plain>The levels were checked monthly during pregnancy </plain></SENT>
<SENT sid="7" pm="."><plain>Most women required 5,000U Fragmin once daily during the first trimester unless they were greater than 100 kg at the start of pregnancy </plain></SENT>
<SENT sid="8" pm="."><plain>The mean time for dosage increase was 20.5 week (S.D </plain></SENT>
<SENT sid="9" pm="."><plain>8.2) </plain></SENT>
<SENT sid="10" pm="."><plain>26/34 pregnancies (76%) required 5,000 twice daily at the end of pregnancy </plain></SENT>
<SENT sid="11" pm="."><plain>Epidural anaesthesia was managed by omitting Fragmin dose or inserting the needle 6 hours after the previous Fragmin injection </plain></SENT>
<SENT sid="12" pm="."><plain>There were no <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> <z:hpo ids='HP_0001873'>thrombocytopenias</z:hpo> or excessive haemorrhage </plain></SENT>
<SENT sid="13" pm="."><plain>One woman had osteoporotic <z:hpo ids='HP_0002953'>vertebral collapse</z:hpo> post partum, she had no other risk factors for <z:hpo ids='HP_0000939'>osteoporosis</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>LWM <z:chebi fb="5" ids="28304">heparin</z:chebi> (Fragmin) appears to be efficacious in preventing recurrent <z:hpo ids='HP_0001907'>thromboembolic disease</z:hpo> in pregnant women at high risk, but it is notable that <z:e sem="disease" ids="C0521170" disease_type="Disease or Syndrome" abbrv="">osteoporotic fractures</z:e> occurred post partum in one woman </plain></SENT>
<SENT sid="15" pm="."><plain>Further trials are required to determine optimal dosage and safety </plain></SENT>
</text></document>